Qualigen Therapeutics, Inc. — Director's Dealing 2017

Oct 27, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RITTER PHARMACEUTICALS INC (RTTR)
CIK: 0001460702
Period of Report: 2017-10-03

Reporting Person: Ritter Ira E. (Director, Exec. Chairman, CSO, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-10-03	Common Stock	P	187500	—	Acquired	1004772	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-10-03	Warrants (right to buy)	$.44	P	187500	Acquired	2022-10-03	Common Stock (187500)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	6250	Indirect

Footnotes

F1: Stonehenge Partners LLC ("Stonehenge") purchased 187,500 Class A Units of the Issuer, consisting of 187,500 shares of common stock and warrants to purchase 187,500 shares of common stock, in the Issuer's October 2017 public offering at the public offering price of $0.40 per Class A Unit. The shares of common stock and warrants that are part of the Class A Units sold to Stonehenge in the puble offering were immediately separable and were issued separately in the offering.

F2: As a managing partner of Stonehenge the Reporting Person may be deemed the beneficial owner of these shares. The Reporting Person expressly disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein.

F3: These shares are held in a retirement plan trust of which the Reporting Person and his spouse are trustees. The Reporting Person's spouse and the revocable trust of the Reporting Person and his spouse are beneficiaries of the retirement plan trust. The Reporting Person expressly disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.